

May 29, 2018

BSE Limited

The Corporate Relationship Department

P.J. Towers,

Dalal Street,

Mumbai - 400001

Scrip Code: 540788

Dear Sir/ Madam,

Sub: Outcome of meeting of the Board of Directors of Aspira Pathlab & Diagnostics Limited

This is to inform you that the Board of Directors of the Company, at their meeting held today at 11.30 a.m. has:

1. Approved the Audited Standalone financial results of the Company for the quarter and year ended 31st March, 2018.
2. Ratified the appointment of Statutory Auditor of the Company for the financial year 2018-19 subject to approval of shareholders in the ensuing Annual General Meeting.
3. Approved the appointment of S K Pandey, Company Secretary in Practice as Secretarial Auditor of the Company u/s 204 of the Companies Act, 2013 for the financial Year 2018-19.
4. Approved the appointment of M/s CNK & Associates LLP, Chartered Accountants as Internal Auditor of the Company for the financial year 2018-19.

The meeting of the Board of Directors was concluded at 3.30 p.m.

The Above financial results along with the Auditors Report on the financial results are enclosed herewith along with a declaration stating that Auditor's reports have unmodified opinion.


Kindly take the same on your records.


Thanking you.

Yours faithfully,

For **ASPIRA PATHLAB & DIAGNOSTIC LIMITED**

(Formerly known as Utkal Soap Products Ltd)


Mamta Mav
Company Secretary



May 29, 2018

BSE Limited
The Corporate Relationship Department
P.J. Towers, Dalal Street,
Mumbai - 400001
Scrip Code: 540788

Ref: SEBI Circular No. CIR/CFD/CMD/56/2016 dated 27th May, 2016.

Sub: Declaration pursuant to Regulation 33(3)(d) of the Securities & Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Dear Sir,

I, Dr. Chander Puri (DIN: 06886988), Executive Director & CEO of the Company, hereby declare that the Statutory Auditor of the Company M/S P Khetan & Co., Chartered Accountant (FRN: 327386E) have issued an Audit Report with unmodified opinion on standalone Audited Financial Results of the Company for year ended on March 31, 2018.

This declaration is given in compliance to regulation 33 (3) (d) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended by the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2016 vide notification No. SEBI/ LAD- NRO/ GN/ 2016-17/ 001 dated May 25, 2016 and Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016.

You are requested to take the same on your record.

Thanking you,

For Aspira Pathlab & Diagnostics Limited


Dr. Chander Puri
Executive Director & CEO
DIN: 06886988



Aspira Pathlab & Diagnostics Limited
(Formerly known as Utikal Soap Products Limited)
(CIN L85100MH1973PLC289209)

Reg. Office : Flat No. 2, R.D. Shah Bldg., Shradhdhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai -400086
Statement of Audited Financial Result for the Quarter ended and Year ended 31st March 2018

(Rs. in Lakhs)

Particulars	Quarter ended			Year ended	
	31-Mar-18 (Audited)	31-Dec-17 (Unaudited)	31-Mar-17 (Audited)	31-Mar-18 (Audited)	31-Mar-17 (Audited)
1. Income					
(a) Revenue from Operations					
Sales/Income from Operations	147.26	126.15	60.57	435.78	75.88
Other Operating Income	-	-	-	-	-
(b) Other Income	6.82	4.36	7.18	22.05	30.87
Total Income	154.08	130.51	67.75	457.83	106.75
2. Expenses					
(a) Cost of Materials consumed	54.46	26.97	12.27	130.18	14.22
(b) Purchase of stock-in-trade	-	-	-	-	-
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
(d) Employee benefits expense	98.32	90.95	66.83	342.38	161.18
(e) Finance Costs	28.78	17.76	7.64	80.48	25.78
(f) Depreciation and amortisation expense	12.98	39.97	15.82	112.46	19.95
(g) Other expenses	96.62	89.23	68.96	350.56	158.11
Total Expenses	291.16	264.88	171.52	1,016.06	379.24
3. Profit / (Loss) before exceptional items and tax (1-2)	(137.08)	(134.37)	(103.77)	(558.23)	(272.49)
4. Exceptional Items	-	-	-	-	-
5. Profit / (Loss) before tax (3+4)	(137.08)	(134.37)	(103.77)	(558.23)	(272.49)
6. Tax Expenses	-	-	0.02	-	0.02
7. Profit / (Loss) after tax (5-6)	(137.08)	(134.37)	(103.75)	(558.23)	(272.47)
8. Other Comprehensive income (net of tax)	-	-	-	-	-
9. Total Comprehensive income (7+8)	(137.08)	(134.37)	(103.75)	(558.23)	(272.47)
10. Paid up Equity share capital (face value 10 each)	519.30	519.30	519.30	519.30	519.30
11. Earning per share					
(a) Basic	(2.64)	(2.59)	(2.07)	(10.75)	(8.12)
(b) Diluted	(2.64)	(2.59)	(2.07)	(10.75)	(8.12)

Note

- The above audited financial results were reviewed by Audit Committee and approved by the Board of Directors in their meeting held on 29.05.18.
- The previous period figures have been regrouped wherever necessary.
- The Statutory auditors of the Company have carried out audit of above results as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.
- The Company has adopted Indian Accounting standards (Ind AS) prescribed under Section 133 of the Companies Act 2013 read with Companies (Indian Accounting Standard) Rules, 2015, with effect from 01st April, 2017. The date of transition to Ind AS 01st April, 2016 and accordingly, the above results have been prepared in accordance with recognition and measurement principles laid down in Ind AS 34 on Interim Financial Reporting and other accounting principles generally accepted in India. The impact of transition has been accounted for in the opening reserves and the comparative period figures have been reinstated accordingly.
- The figures of the last quarter are the balancing figures between audited figures in respect of full financial year and the published year to date figures, i.e upto third quarter of financial year.
- The reconciliation of net profit or loss reported in accordance with GAAP to total comprehensive income in accordance with Ind AS given below

Description	Quarter ended 31st March, 2017	Year ended 31st March, 2017
Net profit/(Loss) as per previous GAAP (Indian GAAP)	(107.60)	(276.32)
Ind AS Adjustment : Add/(Less)	0.00	0.00
Reversal of amortisation of goodwill previously booked in prior GAAP (Net of Tax)	3.90	3.90
Effect of measuring Security Deposit at fair value	(0.05)	(0.05)
Net profit/(Loss) as per Ind AS	(103.75)	(272.47)
Other Comprehensive Income	0.00	0.00
Total Comprehensive income for the period	(103.75)	(272.47)

7. Reconciliation of total equity for previous period as reported under previous GAAP to as reported under Ind AS:

Description	31-Mar-17
Equity (Shareholders Fund) as per previous GAAP	587.76
Adjustments:	
Reversal of amortisation of goodwill previously booked in prior GAAP (Net of Tax)	3.90
Effect of measuring Security Deposit at fair value	(0.05)
Equity as per Ind AS	591.61

- The reconciliation statement has been provided in accordance with circular CIR/CFD/FAC/62/2016 issued by SEBI dated July 5th, 2016 on account of implementation of Ind AS by listed Companies

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Name : Balkrishna S Talawadekar
Designation : Chief Financial Officer

Place : Mumbai
Date : 29.05.2018



ASPIRA PATHLAB & DIAGNOSTICS LIMITED

(Formerly known as Utkal Soap Products Limited)

CIN : L85100MH1973PLC289209

Flat No. 2, R D Shah Bldg., Shraddhanand Road

Opp: Rly St. Ghatkopar (W), Mumbai -400086

Tel No. 022-71975756 Mail ID :support@aspiradiagnostics.com

Website : www.aspiradiagnostics.com

Statement of Assets and Liabilities for Companies (Other than Banks)

(Rs. In Lakhs)

	As at 31st March 2018 (Audited)	As at 31st March, 2017 (Audited)
A ASSEST		
Non-current assets		
Property, plant and equipment	685.20	669.43
Capital work-in -progress	-	24.52
Goodwill	94.24	94.24
Other Intangible assets	11.09	15.26
Financial Assests		
(i) Investments	-	-
(ii) Loans	58.75	59.60
(iii) Others	225.00	225.00
Deffered tax assets (net)	-	-
Other Non-current financial assests	-	-
Total non-current assets	1,074.28	1,088.05
Current Assets		
Inventories	36.94	11.91
Financial Assests		
(i) Trade Receivables	35.48	8.70
(ii) Cash and Cash Equivalents	22.10	281.04
(iii) Bank balance other than (iii) above	-	-
(iv) Others- Loans & Advances	64.61	48.14
Other Current Assets	19.78	47.87
Total Current Assets	178.91	397.66
Total Assets	1,253.19	1,485.71
B EQUITY AND LIABILITIES		
EQUITY		
Equity share Capital	519.30	519.30
Other equity	(485.82)	72.31
Total Equity	33.48	591.61




[Handwritten Signature]

Particulars	As at 31st March 2018 (Audited)	As at 31st March, 2017 (Audited)
LIABILITIES		
Non-current liabilities		
Financial liabilities		
(i) Borrowings	1,050.31	317.50
(ii) Other Financial liabilities	-	-
Provisions	5.74	1.47
Deferred Tax Liability	-	-
Total non-current liabilities	1,056.05	318.97
Current liabilities		
Financial liabilities		
(i) Borrowings	8.54	361.05
(ii) Trade payables	22.71	28.68
(iii) Other financial liabilities	-	-
Other current liabilities	132.38	184.26
Provisions	0.03	1.14
Current tax liabilities (Net)	-	-
Total current liabilities	163.66	575.13
Total Liabilities	1,219.71	894.10
Total Equity and Liabilities	1,253.19	1,485.71

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Name : Balkrishna S Talawadkar
Designation : Chief Financial Officer

Place : Mumbai
Date : 29.05.2018






P KHETAN & CO
Chartered Accountants

19B B B Ganguly Street
Room No. 5, 2nd Floor
Kolkata – 700012
Phone- 033-40734009
Mobile- 9883093350
e-mail- khetanpk@gmail.com

Independent Auditor's Report On Annual Standalone Financial Results of Aspira Pathlab & Diagnostics Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To
The Board of Directors,
Aspira Pathlab & Diagnostics Limited
(formerly known as Utkal Soap Products Limited)
Flat No.2 , R.D. Shah Bldg, Shradhdhanand Road
Opp. Ghatkopar Railway Station
Ghatkopar (West), Mumbai- 400086

We have audited the accompanying statement of Standalone financial results of **Aspira Pathlab & Diagnostics Limited** (formerly known as Utkal Soap Products Limited) for the year ended March 31, 2018 ('Standalone financial results'), attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by circular no. CIR/CFD/FAC/62/2016 dated 5 July, 2016. Attention is drawn to the fact that the figures for the quarter ended 31st March 2018 and corresponding quarter ended in the previous year as reported in these standalone financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the end of third quarter of the relevant financial year. Also the figures upto the end of third quarter for the current and previous financial year had only been reviewed and not subjected to audit.

These Standalone financial results have been prepared on the basis of annual standalone IND AS financial statements and reviewed quarterly standalone financial results upto the end of third quarter which are the responsibility of the company's management. Our responsibility is to express an opinion on these annual standalone financial results based on our audit of the annual standalone Ind AS financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard ('Ind AS') prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; as applicable and other accounting principles generally accepted in India and in compliance with regulation 33 of the Listing Regulations.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the annual standalone financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as the annual standalone financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

The comparative standalone financial results for the quarter and year ended 31st March 2017, included in the statement are based on the previously issued standalone financial results of the company, prepared in accordance with the accounting standards specified under section 133 of the companies act 2013 read with Rule 7 of the companies (Accounts) Rules, 2014 ('previous GAAP') on which we have expressed an unmodified opinion. Management has adjusted these results for the differences in the accounting principles adopted by the company on the transition to the Indian Accounting Standard ("Ind AS") and presented a reconciliation of Profit/(Loss) under Ind AS of the corresponding quarter and year ended 31st March 2017 with the Profit/(Loss) reported under previous GAAP which have been approved by the Company's Board of Directors and have been audited by us.



P KHETAN & CO
Chartered Accountants

19B B B Ganguly Street
Room No. 5, 2nd Floor
Kolkata – 700012
Phone- 033-40734009
Mobile- 9883093350
e-mail- khetanpk@gmail.com

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- (i) Have been presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (ii) give a true and fair view of the Standalone net profit/(loss) and other comprehensive income and other financial information for the year ended 31st March 2018.

For P Khetan & Co
Chartered Accountant

Pankaj Khetan

(Pankaj Kumar Khetan)
Partner

M.No- 066080

Firm Reg. No- 327386E

Place- Kolkata

Date- 29.05.2018

